Amendment to: Predicting Recurrence Risk in Resected Stage I-III Melanoma Through Circulating Tumor DNA Analysis - Takeaways - MDSpire

Amendment to: Predicting Recurrence Risk in Resected Stage I-III Melanoma Through Circulating Tumor DNA Analysis

  • By

  • Mengke Zhao

  • Lianjun Zhao

  • Yueling Yang

  • Fufeng Wang

  • Jiani Yin

  • Xiaoying Wu

  • Yu Ren

  • Xinyu Su

  • Yirong Wu

  • Luqiao Li

  • Rong Huang

  • Kelin Zheng

  • JiaYu Wang

  • Zhengyun Zou

  • January 27, 2026

  • 0 min

Share

  • 1

    An amendment was made to the article regarding the prediction of recurrence risk in melanoma.

  • 2

    Lianjun Zhao is now recognized as a co-first author of the article.

  • 3

    The original article was published in BMC Cancer, volume 25, article 1808.

  • 4

    The DOI for the article is 10.1186/s12885-025-15093-w.

  • 5

    The amendment addresses an error in the author group of the original publication.

Original Source(s)

Amendment to: Predicting Recurrence Risk in Resected Stage I-III Melanoma Through Circulating Tumor DNA Analysis

  • by Mengke Zhao, Lianjun Zhao, Yueling Yang, Fufeng Wang, Jiani Yin, Xiaoying Wu, Yu Ren, Xinyu Su, Yirong Wu, Luqiao Li, Rong Huang, Kelin Zheng, JiaYu Wang, Zhengyun Zou

  • January 27, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen

Author Correction: The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2